Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors

Name
Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors
Accession Number
DBCAT003788
Description

Not Available

Drugs
DrugDrug Description
AlirocumabA PCSK9 inhibitor used as an adjunct to manage heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients who require additional lowering of LDL-cholesterol (LDL-C).
InclisiranA PCSK9-targeting short interfering RNA (siRNA) that lowers plasma LDL-cholesterol levels.
Drugs & Drug Targets
DrugTargetType
AlirocumabProprotein convertase subtilisin/kexin type 9target
InclisiranProprotein convertase subtilisin/kexin type 9target